Autolus Therapeutics (NASDAQ:AUTL) Receives "Buy" Rating from Needham & Company LLC

Key Points

• Autolus Therapeutics received a reaffirmed "Buy" rating from Needham & Company LLC, with a target price set at $10.00.
• The stock has experienced a decline of 3.6%, trading at about $1.62, with a market capitalization of $431.15 million.
• Various analysts have differing opinions on the stock, including six with a Buy rating and one with a Sell rating, resulting in an average rating of "Moderate Buy" and an average target price of $9.12.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently have a $10.00 target price on the stock.

AUTL has been the subject of several other reports. Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. William Blair reissued an "outperform" rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Autolus Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $9.12.

Autolus Therapeutics Stock Down 3.6%

Shares of NASDAQ AUTL opened at $1.62 on Monday. The stock's 50 day moving average price is $1.59 and its two-hundred day moving average price is $1.79. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $5.00. The stock has a market capitalization of $431.15 million, a P/E ratio of -1.93 and a beta of 1.84.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. On average, analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AUTL. Marex Group plc acquired a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at $28,000. R Squared Ltd acquired a new position in Autolus Therapeutics during the second quarter worth $50,000. Invesco Ltd. increased its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after buying an additional 11,381 shares during the last quarter. Delaney Dennis R acquired a new stake in shares of Autolus Therapeutics in the second quarter valued at about $55,000. Finally, Forefront Wealth Management Inc. acquired a new stake in shares of Autolus Therapeutics in the second quarter valued at about $61,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.